Chemotherapy-resistant human acute myeloid leukemia (AML) cells are thought to be enriched
in quiescent immature leukemic stem cells (LSC). To validate this hypothesis in vivo, we …

FLT3 mutations are found in 30% of AML cases and are actionable by tyrosine kinase
inhibitors. Here, we discovered that C/EBPα regulates FA biosynthesis and protection from lipid …

Autophagy has been associated with oncogenesis with one of its emerging key functions
being its contribution to the metabolism of tumors. Therefore, deciphering the mechanisms of …

Therapy resistance represents a major clinical challenge in acute myeloid leukemia (AML).
Here we define a ‘MitoScore’ signature, which identifies high mitochondrial oxidative …

Mutations in IDH induce epigenetic and transcriptional reprogramming, differentiation bias,
and susceptibility to mitochondrial inhibitors in cancer cells. Here, we first show that cell lines, …

Objectives We previously reported the prognostic value of serum ferritin in younger patients
with intermediate‐risk acute myeloid leukemia (AML). The aims of this study were to confirm …

CD36 promotes blast migration and extramedullary disease in acute myeloid leukemia and
represents a critical target that can be exploited for clinical prognosis and patient treatment. …

Drug tolerant/resistant leukemic stem cell (LSC) subpopulations may explain frequent
relapses in acute myeloid leukemia (AML), suggesting that these relapse-initiating cells (RICs) …

Extracellular ATP and CD39–P2RY13–cAMP–OxPHOS axis are key regulators of cytarabine
resistance, offering a new promising therapeutic strategy in AML. This article is highlighted …

These findings demonstrate the role of myeloperoxidase in the regulation of ROS levels and
sensitivity of AML cells to cytarabine, an essential chemotherapeutic backbone in the …